NCT00003528View on ClinicalTrials.gov

Raltitrexed in Treating Children With Refractory Acute Leukemia

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

September 30, 1998

Primary Completion Date

June 30, 2002

Conditions
Recurrent Childhood Acute Lymphoblastic LeukemiaRecurrent Childhood Acute Myeloid Leukemia
Interventions
DRUG

raltitrexed

Given IV

Trial Locations (1)

1205

Swiss Pediatric Oncology Group - Geneva, Geneva

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00003528 - Raltitrexed in Treating Children With Refractory Acute Leukemia | Biotech Hunter | Biotech Hunter